MI SB0991

Authorizes eligible patients with advanced illnesses to access investigational drugs, biological products, or devices that have completed Phase 1 clinical trials but lack FDA approval.

Requires eligible patients to have an advanced illness, consider all FDA-approved treatments, receive physician recommendation, and provide written informed consent that includes potential risks and financial liability.

Prohibits manufacturers from being required to provide investigational treatments and allows them to provide treatments free or charge patients for manufacturing costs.

Prevents health insurers and governmental agencies from being required to cover costs of investigational treatments and protects health care providers from license revocation or discipline solely for recommending such treatments.

Shields manufacturers and other entities from private lawsuits resulting from investigational treatment if they comply in good faith with the act and exercise reasonable care.